Project Details
Description
A Randomized, Open Label, Multinational Phase 3 Trail Comparing Amrubibin Versus Topotecan in Patients with Extensive or Limited and Sensative or Refractory Small Cell Lung Cancer after Failure of First Line Chemotherapy
| Status | Finished |
|---|---|
| Effective start/end date | 4/1/08 → 4/24/12 |
Funding
- CELGENE CORPORATION
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.